Arcadia Wealth Management Inc. Takes Position in Pfizer Inc. (NYSE:PFE)

Arcadia Wealth Management Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 19,850 shares of the biopharmaceutical company's stock, valued at approximately $527,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Wood Tarver Financial Group LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $51,000. Copley Financial Group Inc. grew its position in shares of Pfizer by 15.3% in the 4th quarter. Copley Financial Group Inc. now owns 22,973 shares of the biopharmaceutical company's stock valued at $609,000 after acquiring an additional 3,050 shares during the period. American Investment Services Inc. bought a new position in shares of Pfizer in the 4th quarter valued at about $371,000. BridgePort Financial Solutions LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $331,000. Finally, Park Square Financial Group LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $128,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PFE shares. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Performance

NYSE PFE traded up $0.26 during trading on Thursday, reaching $23.44. The company's stock had a trading volume of 26,079,398 shares, compared to its average volume of 41,037,991. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $133.26 billion, a price-to-earnings ratio of 16.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a 50 day moving average price of $23.22 and a 200 day moving average price of $25.11.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.82 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.